Guggenheim analyst Michael Schmidt raised the firm’s price target on Tango Therapeutics (TNGX) to $12 from $10 and keeps a Buy rating on the shares after the company disclosed Phase 1/2 vopimetostat data in solid tumor patients. The firm is updating its model and estimates and increasing its odds of success assumption for vopimetostat following the data.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX: